Back to top
more

MacroGenics (MGNX)

(Delayed Data from NSDQ)

$1.61 USD

1.61
302,820

-0.08 (-4.73%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $1.62 +0.01 (0.62%) 6:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

SNDL Inc. (SNDL) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

SNDL INC (SNDL) delivered earnings and revenue surprises of +125.00% and +6.13%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

AtriCure (ATRC) delivered earnings and revenue surprises of +86.67% and +4.61%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies

by Zacks Equity Research

Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies are part of the Zacks Industry Outlook article.

Indrajit Bandyopadhyay headshot

4 Medical Product Stocks to Watch From a Challenging Industry

by Indrajit Bandyopadhyay

The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR reflect the favorable fundamentals.

Zacks Equity Research

MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

MacroGenics (MGNX) delivered earnings and revenue surprises of -6.56% and 5.45%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Rockwell Medical (RMTI) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rockwell Medical (RMTI) delivered earnings and revenue surprises of -33.33% and 6.26%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Owens & Minor (OMI) Q1 Earnings Top Estimates

by Zacks Equity Research

Owens & Minor (OMI) delivered earnings and revenue surprises of 15% and 1.43%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Biote Corp. (BTMD) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

biote Corp. (BTMD) delivered earnings and revenue surprises of 33.33% and 3.51%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Indrajit Bandyopadhyay headshot

4 Medical Product Stocks to Buy From a Challenging Industry

by Indrajit Bandyopadhyay

The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR are likely to gain from the favorable factors.

Zacks Equity Research

MacroGenics (MGNX) Loses -48.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

The heavy selling pressure might have exhausted for MacroGenics (MGNX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

MacroGenics (MGNX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for MacroGenics (MGNX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

MacroGenics (MGNX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

MacroGenics (MGNX) delivered earnings and revenue surprises of -8.70% and 57.24%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Capricor Therapeutics (CAPR) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Capricor (CAPR) delivered earnings and revenue surprises of 48.39% and 248.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

High Tide Inc. (HITI) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

High Tide (HITI) delivered earnings and revenue surprises of -100% and 4.46%, respectively, for the quarter ended January 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Apyx Medical (APYX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Apyx (APYX) delivered earnings and revenue surprises of 7.69% and 0.16%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's What Key Metrics Tell Us About MacroGenics (MGNX) Q3 Earnings

by Zacks Equity Research

The headline numbers for MacroGenics (MGNX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

MacroGenics (MGNX) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

MacroGenics (MGNX) delivered earnings and revenue surprises of 429.41% and 14.09%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Capricor (CAPR) Surges 18.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

Capricor (CAPR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Do Options Traders Know Something About MacroGenics (MGNX) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to MacroGenics (MGNX) stock based on the movements in the options market lately.

Zacks Equity Research

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Zacks Equity Research

Compared to Estimates, MacroGenics (MGNX) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for MacroGenics (MGNX) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

MacroGenics (MGNX) delivered earnings and revenue surprises of -89.36% and 55.28%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Boston Scientific (BSX) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Boston Scientific (BSX) delivered earnings and revenue surprises of 6.90% and 2.51%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

MacroGenics (MGNX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

MacroGenics (MGNX) delivered earnings and revenue surprises of -188.46% and 58.29%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate MacroGenics (MGNX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

MacroGenics (MGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.